Pregnancy

Cannabis legalization has led to a boom in potent forms of the drug that present new hazards for adolescents

Retrieved on: 
Mardi, avril 23, 2024

When other drugs would occasionally come up, I didn’t understand some of the slang terms they used for these drugs.

Key Points: 
  • When other drugs would occasionally come up, I didn’t understand some of the slang terms they used for these drugs.
  • Many people may have that feeling now when the topic of cannabis comes up – especially in its different and newer forms.
  • A major change during my time in research is the legalization and explosion of cannabis availability across the U.S.

A shifting landscape

  • It also serves as a catch-all term for any substance with chemical compounds from cannabis plants and addresses concerns that the word marijuana has some long-standing racist overtones.
  • Cannabis now comes in a larger variety of forms than it used to.
  • These include oils that can be vaporized by vape or dab pens, waxier substances and even powders.

How cannabis derivatives interact with the brain

  • Each one interacts with the brain in different ways, producing different perceived effects.
  • The differences between THC and CBD come from how they interact with cannabinoid receptors – the proteins onto which these drugs attach – in the brain and body.

The changing nature of cannabis products

  • By increasing the amount of THC, concentrated products can increase blood levels of THC rapidly and more strongly than nonconcentrates such as traditional smoked cannabis.
  • Cannabis concentrates also come in many different forms that range from waxy or creamy to hard and brittle.
  • They are made in a variety of ways that may require dry ice, water or flammable solvents such as butane.
  • The myriad names for cannabis concentrates can be confusing.

Cannabis use and adolescents

  • A 2021 systematic review found that past-year cannabis vaping nearly doubled from 2017 to 2020 in adolescents - jumping from 7.2% to 13.2%.
  • In addition, a 2020 study found that one-third of adolescents who vape do so with cannabis concentrates.
  • Cannabis use by adolescents is scary because it can alter the way their brains develop.
  • Adolescents who use cannabis are also more likely to experience symptoms of schizophrenia, struggle more in school and engage in other risky behaviors.
  • This article is part of Legal cannabis turns 10, a series examining the impact of a decade of recreational cannabis use.


Ty Schepis receives funding from US Food and Drug Administration and the National Institute on Drug Abuse. His research is also supported by a faculty fellowship from the Texas State University Translational Health Research Center.

Type 2 diabetes is not one-size-fits-all: Subtypes affect complications and treatment options

Retrieved on: 
Vendredi, avril 19, 2024

You may have heard of Ozempic, the “miracle drug” for weight loss, but did you know that it was actually designed as a new treatment to manage diabetes?

Key Points: 
  • You may have heard of Ozempic, the “miracle drug” for weight loss, but did you know that it was actually designed as a new treatment to manage diabetes?
  • In Canada, diabetes affects approximately 10 per cent of the general population.

Locks and keys

  • Every cell in the body needs sugar as an energy source, but too much sugar can be toxic to cells.
  • This equilibrium needs to be tightly controlled and is regulated by a lock and key system.
  • Cells cover themselves with locks that respond perfectly to insulin keys to facilitate the entry of sugar into cells.
  • The body can encounter difficulties producing an adequate number of insulin keys, and/or the locks can become stubborn and unresponsive to insulin.

Severe insulin-deficient diabetes: We’re missing keys!

  • In the severe insulin-deficient diabetes (SIDD) subtype, the key factories — the beta cells — are on strike.
  • Why the beta cells go on strike remains largely unknown, but since there is an insulin deficiency, treatment often involves insulin injections.

Severe insulin-resistant diabetes: But it’s always locked!

  • In the severe insulin-resistant diabetes (SIRD) subtype, the locks are overstimulated and start ignoring the keys.
  • There are many treatment avenues for these patients but no consensus about the optimal approach; patients often require high doses of insulin.

Mild obesity-related diabetes: The locks are sticky!

  • Mild obesity-related (MOD) diabetes represents a nuanced aspect of Type 2 diabetes, often observed in individuals with higher body weight.
  • The locks are “sticky,” so it is challenging for the key to click in place and open the lock.

Mild age-related diabetes: I’m tired of controlling blood sugar!


Mild age-related diabetes (MARD) happens more often in older people and typically starts later in life. With time, the key factory is not as productive, and the locks become stubborn. People with MARD find it tricky to manage their blood sugar, but it usually doesn’t lead to severe complications. Among the different subtypes of diabetes, MARD is the most common.

Unique locks, varied keys

  • In Canada, unique cases of Type 2 diabetes were identified in Indigenous children from Northern Manitoba and Northwestern Ontario by Dr. Heather Dean and colleagues in the 1980s and 90s.
  • Read more:
    Indigenous community research partnerships can help address health inequities

    Childhood-onset Type 2 diabetes is on the rise across Canada, but disproportionately affects Indigenous youth.

  • Acknowledging this distinct subtype of Type 2 diabetes in First Nations communities has led to the implementation of a community-based health action plan aimed at addressing the unique challenges faced by Indigenous Peoples.

A mosaic of conditions

  • Type 2 diabetes is not uniform; it’s a mosaic of conditions, each with its own characteristics.
  • Since diabetes presents so uniquely in every patient, even categorizing into subtypes does not guarantee how the disease will evolve.


Lili Grieco-St-Pierre receives funding from Fonds de recherche du Québec - Santé (FRQS). Jennifer Bruin receives funding from the Canadian Institutes of Health Research (CIHR), Natural Sciences and Engineering Research Council of Canada (NSERC), JDRF, Diabetes Canada.

The world’s oldest conjoined twins have died – what we know about this rare condition

Retrieved on: 
Vendredi, avril 19, 2024

The world’s oldest conjoined twins, Lori and George Schappell, recently died, aged 62.

Key Points: 
  • The world’s oldest conjoined twins, Lori and George Schappell, recently died, aged 62.
  • Conjoined twins are incredibly rare, accounting for about one or two in every 100,000 births.
  • Because conjoined twins are so rare, it is difficult to know exactly how they come about.

Types of conjoined twins

  • There are 15 recognised types of conjoined twins, based on the various places their bodies fuse.
  • Conjoined twins are usually picked up on routine ultrasound scans performed during pregnancy.
  • Conjoined twins who are diagnosed by imaging are typically delivered by caesarean section.

Separating twins

  • One of the longest operations to separate conjoined twins, who were fused at the cranium, took more than 100 hours.
  • The earliest recorded attempt at surgical separation of conjoined twins dates back to AD945 in Armenia where conjoined brothers lived until middle age before one of them died.
  • Separating conjoined twins requires a significant amount of planning before surgery can begin, including, of course, lots of imaging such as ultrasound, CT and MRI.
  • Twins who share vital organs – or whose organs are fused – have a lower chance of a successful separation.


Adam Taylor does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

The tragedy of sudden unexpected infant deaths – and how bedsharing, maternal smoking and stomach sleeping all contribute

Retrieved on: 
Jeudi, avril 18, 2024

Sudden unexpected infant death, or SUID, occurs in infants less than 1 year old who die suddenly and unexpectedly without an obvious cause before investigation, accounting for about 3,400 deaths annually in the U.S..

Key Points: 
  • Sudden unexpected infant death, or SUID, occurs in infants less than 1 year old who die suddenly and unexpectedly without an obvious cause before investigation, accounting for about 3,400 deaths annually in the U.S..
  • These infants die from sudden infant death syndrome, or SIDS, accidental suffocation and strangulation in bed, or other ill-defined and unknown causes.
  • Compared with nonsharing infants in our study, bedsharing infants were more likely to have the following characteristics:


Among nonsharing infants in the study, only one-third were sleeping in the recommended back position, and three-quarters were in sleep areas that had soft bedding such as pillows, comforters or bumper pads at the time of death. Three-quarters of all the sudden unexpected infant deaths in our study were affected by multiple unsafe sleep factors.

Why it matters

  • Rates of sudden unexpected infant deaths overall in the U.S. have changed only minimally in the past 20 years, but racial-ethnic disparities [in these deaths are widening] due to increasing rates among non-Hispanic Black infants.
  • Our study suggests that the majority of these deaths are preventable by following the guidelines for safe infant sleep as outlined by the American Academy of Pediatrics and the National Institute of Child Health and Human Development.
  • Even with knowledge of the recommended practices, many parents find it difficult to follow the recommendations.
  • Others may choose not to follow them or may not follow them all of the time.
  • Bedsharing may also be a common cultural or preferred practice, so not doing so might go against one’s beliefs or preferences.

What’s next

  • Much more research is needed to find the most effective ways to teach families about safe infant sleep.
  • There are currently a number of studies underway using innovative methods to engage and educate parents, starting in pregnancy and continuing after the baby is born.


Fern R. Hauck receives funding from NIH. She is affiliated with American Academy of Pediatrics Task Force on SIDS.

Draft template for assessment report for the development of European herbal monographs and European Union list entries - Revision 6

Retrieved on: 
Jeudi, avril 18, 2024

The completed comments form should be sent to

Key Points: 
    • The completed comments form should be sent to
      [email protected]
      10
      11
      Keywords

      Committee on Herbal Medicinal Products; HMPC; European Union herbal
      monographs; European Union list of herbal substances, preparations and
      combinations thereof for use in traditional herbal medicinal products; herbal
      medicinal products; traditional herbal medicinal products; traditional use;
      well-established medicinal use; benefit-risk assessment; assessment report

      12

      1
      2

      Changes introduced in section 6 Overall conclusions.

    • Peer-reviewer

      If not the same peer-reviewer
      since last version, all peerreviewers should be listed, and
      the version specified in
      brackets.

    • 22

      23


      on
      .

    • It is a working

      24

      document, not yet edited, and shall be further developed after the release for consultation of the

      25


      .

    • The principle of the template is to make clear
      distinctions between presentation of data (methodology and results)
      and the assessment of the data (?assessor?s comment?).
    • likely from an article but it seems it is concluded by
      the rapporteur; ?According to the author? to be added.
    • Chapters with
      a heading including the word ?conclusion? should include a summary
      of all critical assessment of the assessor for that particular
      chapter.
    • If an assessor?s comment is not needed, the Rapporteur
      should delete the box inserted in the template.
    • ?
      The report should be sufficiently detailed to allow for secondary
      assessment of the available data by other HMPC experts.
    • Overview of available pharmacokinetic data regarding the herbal substance(s), herbal
      preparation(s) and relevant constituents thereof ........................................................... 16

      97
      98

      3.3.

    • Overall conclusions on clinical pharmacology and efficacy ........................................ 27

      Assessment report on
      EMA/HMPC/418902/2005

      Page 4/41

      119

      5.

    • This sections is related to
      available quality standards and there is no need to repeat information
      on all preparations included in the monograph.
    • Search and assessment methodology

      161

      The Rapporteur shall undertake a comprehensive search of relevant
      scientific literature and articles, Acts of law and regulations and
      other relevant sources.

    • Cross-reference to the list of
      references in Annex, which should list separately the references
      supporting the assessment report.
    • 143
      144
      145

      150
      151
      152
      153
      154

      162
      163
      164
      165
      166
      167
      168
      169
      170
      171
      172
      173
      174
      175

      Herbal substance(s)

      Herbal preparation(s)

      Relevant constituents for this assessment report

      Examples of scientific databases to be searched are Medline, PubMed,
      Cochrane Database of Systematic Reviews, EMBASE etc.

    • Assessment report on
      EMA/HMPC/418902/2005

      Page 6/41

      176
      177
      178
      179
      180
      181
      182
      183
      184
      185
      186
      187
      188
      189
      190
      191
      192

      Additional relevant references could also be retrieved from the checked
      references.

    • Examples of books are Hagers Handbuch, The Complete German
      Commission E Monographs, PDR for herbal medicines etc.
    • In addition, information from non-EU regulatory
      authorities for examples Health Canada monographs or WHO monographs
      could be searched, if relevant to herbal substances and preparations in
      EU.
    • 221

      225
      226
      227

      232

      When the assessment report is revised, the rapporteur should briefly
      summarise the main changes under this section.

    • Data are collected using the template entitled ?Document
      for information exchange for the preparation of the assessment report
      for the development of European Union monographs and for inclusion of
      herbal substance(s), preparation(s) or combinations thereof in the
      list? (EMEA/HMPC/137093/2006).
    • Assessment report on
      EMA/HMPC/418902/2005

      Page 8/41

      Herbal substance/

      Indication

      Posology and
      method of

      preparation

      administration

      Posology, age
      groups,
      pharmaceutical
      form, method of
      administration,
      duration of use
      As reported in
      the market
      overview

      As reported in
      the market
      overview

      As reported in
      the market
      overview.

    • Assessment report on
      EMA/HMPC/418902/2005

      Page 10/41

      Herbal substance/

      Indication/Medicinal

      Posology and

      preparation

      use

      method of
      administration

      Posology, age
      groups,
      pharmaceutical
      form, method of
      administration,
      duration of use

      Regulatory Status

      Type of
      regulatory
      status where
      possible, date,
      Country

      287

      This overview is not exhaustive.

    • Clinical Safety/Pharmacovigilance

      836
      837
      838
      839
      840
      841

      See ?Assessment of clinical safety and efficacy in the preparation of
      EU herbal monographs for well-established and traditional herbal
      medicinal products?(EMA/HMPC/104613/2005) for further details.

    • Overall conclusions on clinical safety

      1067

      1068

      In terms of structure, the conclusion should follow the presentation of
      the results above.

    • Overall conclusions

      1092

      1093

      1101

      Describe key aspects only briefly, these will already have been
      described in detail in the respective sections.

    • This section should
      cover all recommended ?well-established use? and ?traditional use?
      indications and conclusions shall be provided for each therapeutic
      indication and each herbal preparation.
    • 1102

      Well established use monograph

      1103
      1104

      The clinical studies supporting well-established use should be
      specified for each therapeutic indication and each herbal preparation.

    • The choice for the wording of traditional use indications vis-?vis existing wordings in monographs in the same therapeutic area should
      be briefly discussed/justified.
    • 1153

      List entry

      1154

      The conclusions should include a statement pointing to the
      possibility/non-possibility to support a European Union list entry.

PFAS ‘forever chemicals’: Why EPA set federal drinking water limits for these health-harming contaminants

Retrieved on: 
Mercredi, avril 10, 2024

The U.S. Environmental Protection Agency now believes there is no safe level for two common PFAS – PFOA and PFOS – in drinking water, and it acknowledges that very low concentrations of other PFAS present human health risks.

Key Points: 
  • The U.S. Environmental Protection Agency now believes there is no safe level for two common PFAS – PFOA and PFOS – in drinking water, and it acknowledges that very low concentrations of other PFAS present human health risks.
  • The agency issued the first legally enforceable national drinking water standards for five common types of PFAS chemicals, as well as PFAS mixtures, on April 10, 2024.

What exactly are PFAS?

  • This is a large group of human-made chemicals – currently estimated to be nearly 15,000 individual chemical compounds – that are used widely in consumer products and industry.
  • They can make products resistant to water, grease and stains and protect against fire.
  • The short answer is that PFAS are harmful to human health and the environment.
  • Some of the very same chemical properties that make PFAS attractive in products also mean these chemicals will persist in the environment for generations.
  • The U.S. Geological Survey estimates common types of PFAS are now in at least 45% of the country’s tap water.

What are the health risks from PFAS exposure?

  • Research consistently demonstrates that PFAS are associated with a variety of adverse health effects.
  • A review by a panel of experts looking at research on PFAS toxicity concluded with a high degree of certainty that PFAS contribute to thyroid disease, elevated cholesterol, liver damage, and kidney and testicular cancer.
  • Additionally, current research suggests that babies exposed prenatally are at higher risk of experiencing obesity, early-onset puberty and reduced fertility later in life.
  • Collectively, this is a formidable list of diseases and disorders.

Who’s regulating PFAS?

  • DuPont called it Teflon, which eventually became a household name for its use on nonstick pans.
  • Decades later, in 1998, Scotchgard maker 3M notified the Environmental Protection Agency that a PFAS chemical was showing up in human blood samples.
  • At the time, 3M said low levels of the manufactured chemical had been detected in people’s blood as early as the 1970s.
  • The Agency for Toxic Substances and Disease Registry has a toxicological profile for PFAS.

How can you reduce your PFAS exposure?

  • The best ways to protect yourself and your family from risks associated with PFAS are to educate yourself about potential sources of exposure.
  • Products labeled as water- or stain-resistant have a good chance of containing PFAS.
  • Strategies for monitoring and reporting PFAS contamination vary by location and PFAS source, so the absence of readily available information does not necessarily mean the region is free of PFAS problems.


Kathryn Crawford receives funding from National Institutes of Health and US Geological Survey.

Taking stock of existing barriers to sexual and reproductive health of girls and women in SSA and how collaboration and innovation can help shape the future

Retrieved on: 
Mercredi, avril 10, 2024

For years, women and girls have been failed by a fragmented, under-resourced health system that is not built to meet their sexual and reproductive health needs.

Key Points: 
  • For years, women and girls have been failed by a fragmented, under-resourced health system that is not built to meet their sexual and reproductive health needs.
  • Coupled with HIV, complications during pregnancy and childbirth are the leading cause of death for young women aged 15-19 years.
  • "Tiko" which provides access to free reproductive health services that can change the course of many lives offering youth-friendly care and comprehensive information.
  • Achieving universal access to sexual and reproductive health and rights by 2030 will require close collaboration by stakeholders in developing innovative solutions that can dismantle barriers to access among women and girls.

Bellabeat Unveils Next-Gen IVY Health Tracker for Women: A Leap Forward in Advanced Temperature Tracking and Wellness

Retrieved on: 
Mardi, mars 19, 2024

San Francisco, California--(Newsfile Corp. - March 19, 2024) - In its latest endeavor to revolutionize women's health technology, Bellabeat has launched the new IVY+ Health Tracker.

Key Points: 
  • San Francisco, California--(Newsfile Corp. - March 19, 2024) - In its latest endeavor to revolutionize women's health technology, Bellabeat has launched the new IVY+ Health Tracker.
  • It is equipped with a sophisticated temperature tracking feature, marking a significant advancement in menstrual and fertility tracking.
  • In conjunction with the Bellabeat app, the IVY+ Health Tracker transforms biometric data into actionable wellness insights.
  • The combination of the IVY+ Health Tracker and the Bellabeat app creates a comprehensive health monitoring experience that extends beyond traditional tracking methods.

Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity

Retrieved on: 
Dimanche, avril 7, 2024

ANN ARBOR, Mich., April 07, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced the presentation of results from three pre-specified subgroups from CLEAR Outcomes at the 2024 American College of Cardiology’s Annual Scientific Sessions (ACC.24): women, Hispanic/Latinx, and patients with obesity. These results align with the American College of Cardiology’s robust diversity, equity and inclusion programs to drive cultural change across the profession and ensure that the cardiovascular care team is as diverse as the patients they care for and that all patients are represented in cardiovascular research. The data also reinforce the mission of the ACC: transforming cardiovascular care for all.

Key Points: 
  • “Bempedoic acid is the only FDA approved non-statin LDL lowering therapy to demonstrate reductions in MACE in both primary prevention and secondary prevention patient populations.
  • The Hispanic population is the largest ethnic minority in the U.S., yet is a population historically underrepresented in clinical trials.
  • At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

Philips Foundation and March of Dimes partner to improve prenatal care access in underserved communities, helping address US maternal and infant health challenges

Retrieved on: 
Jeudi, avril 4, 2024

In comparison to other high-income countries, the US still faces the highest maternal mortality rate.

Key Points: 
  • In comparison to other high-income countries, the US still faces the highest maternal mortality rate.
  • While consistent, high-quality prenatal care is an essential component of maternal health and positive birth outcomes, more than 550,000 women receive inadequate prenatal care in the US each year.
  • Mobile healthcare delivery is a proven model to improve access to care.
  • “Every expectant mother should have access to maternal care, yet this is far from reality today.